Global Highly Pathogenic PRRS Live Vaccine Supply, Demand and Key Producers, 2026-2032
The global Highly Pathogenic PRRS Live Vaccine market size is expected to reach $ 20.43 million by 2032, rising at a market growth of 4.1% CAGR during the forecast period (2026-2032).
Highly Pathogenic PRRS Live Vaccine is a modified live swine vaccine used for the prevention of highly pathogenic porcine reproductive and respiratory syndrome, also known as highly pathogenic porcine blue ear disease in China. Major commercial forms include monovalent vaccines based on JXA1-R, TJM-F92, GDr180, HuN4-F112 and related attenuated strains, as well as limited combination vaccines and heat-stabilized formulations containing a highly pathogenic PRRS component. Upstream inputs mainly include attenuated PRRSV seed strains, Marc-145 cells or other suitable cell substrates, culture media, serum or serum-free supplements, stabilizers, lyophilization protectants, diluents, glass vials, rubber stoppers, aluminum caps, labels and cold-chain packaging materials. Downstream customers mainly include integrated swine farming groups, breeding farms, commercial pig farms, veterinary drug distributors, animal disease control institutions and farm technical service providers. In 2025, global production capacity is estimated at around 286 million doses, with sales volume of about 207 million doses and an average ex-factory price of approximately USD 0.070–0.081 per dose; China accounts for the dominant share of both supply and demand, while overseas sales are limited and mainly related to export registration and use in nearby swine-producing markets. This is an approval- and batch-release-driven veterinary biologics segment with a relatively small single-product market size but strong disease-control relevance for pig farms. The estimated industry gross margin in 2025 is around 45%–60%, with leading producers benefiting from larger batch scale, established distribution channels and strain resources, while smaller suppliers face greater margin volatility due to batch size, channel discounts and cold-chain costs.
The current market is mainly supported by disease prevention demand in China's swine farming sector, with supply concentrated among companies that have veterinary biologics manufacturing qualifications, stable batch-release capabilities, mature cell culture processes and strong service capabilities for large-scale pig farms. This is not a globally widespread mass-market vaccine category, but a product segment closely linked to China's highly pathogenic porcine blue ear disease control system, veterinary drug registration framework and practical immunization programs in commercial swine production. Competition is not driven only by price and distribution channels, but also by product safety, batch consistency, field application experience, cold-chain assurance and the supplier's ability to support vaccination programs for farms with different herd health statuses. Demand shows clear structural differentiation. Large-scale pig farming groups and breeding farms place more emphasis on immunization safety, product consistency, strain relevance and long-term supply stability, so their purchasing decisions are generally more cautious. Commercial pig farms and small to medium-sized producers rely more on distributors, regional veterinary service networks and local disease pressure, and are relatively more price-sensitive. As swine farming becomes more consolidated, vaccine suppliers need to move beyond simple product sales and provide vaccination program design, antibody monitoring, herd stabilization management and integrated disease-control advice to strengthen customer stickiness and product value. Future development will focus more on safety improvement, process upgrading, combination vaccines and precision immunization. Traditional modified live vaccines still have advantages in immunogenicity, accumulated field experience and end-user acceptance, but their use will become more cautious in high-health-status farms and production systems pursuing PRRS elimination. Suspension culture can help improve production consistency and scale-up efficiency, heat-stabilized formulations can enhance storage and transportation stability, and combination vaccines can simplify immunization programs. As circulating PRRSV strains continue to evolve, companies also need stronger epidemiological monitoring and clinical validation capabilities to support product iteration and differentiated competition. The main growth drivers include the rising share of large-scale farming, continued investment in major swine disease control, more standardized veterinary vaccine regulation, improvement in farm biosecurity systems and stronger service capabilities among leading suppliers. Key constraints include hog price cycles affecting vaccination budgets, reduced use of live vaccines in some farms pursuing disease elimination, safety concerns related to modified live vaccines, uncertainty in protection caused by regional strain differences, and cost pressure from cold-chain logistics and batch quality control. Overall, this market is more stable and structurally adjusting than high-growth. Future growth will depend less on capacity expansion and more on product quality upgrades, customer concentration and stronger integrated service capabilities among leading companies.
This report studies the global Highly Pathogenic PRRS Live Vaccine production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Highly Pathogenic PRRS Live Vaccine and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Highly Pathogenic PRRS Live Vaccine that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Highly Pathogenic PRRS Live Vaccine total production and demand, 2021-2032, (K Dose)
Global Highly Pathogenic PRRS Live Vaccine total production value, 2021-2032, (USD Million)
Global Highly Pathogenic PRRS Live Vaccine production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (K Dose), (based on production site)
Global Highly Pathogenic PRRS Live Vaccine consumption by region & country, CAGR, 2021-2032 & (K Dose)
U.S. VS China: Highly Pathogenic PRRS Live Vaccine domestic production, consumption, key domestic manufacturers and share
Global Highly Pathogenic PRRS Live Vaccine production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (K Dose)
Global Highly Pathogenic PRRS Live Vaccine production by Type, production, value, CAGR, 2021-2032, (USD Million) & (K Dose)
Global Highly Pathogenic PRRS Live Vaccine production by Application, production, value, CAGR, 2021-2032, (USD Million) & (K Dose)
This report profiles key players in the global Highly Pathogenic PRRS Live Vaccine market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Dahuanong Animal Health, Zoetis, Jilin Teyan Biotechnology, Qingdao Yebio Bioengineering, Sinopharm Yangzhou Vac Biological Engineering, Pulike Biological Engineering, Guangdong WINSUN Bio-pharmaceutical, Sinovetah Biological Pharmaceutical, TECON Pharmaceutical, Harbin Veken Biotechnology, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Highly Pathogenic PRRS Live Vaccine market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Dose) and average price (US$/Dose) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Highly Pathogenic PRRS Live Vaccine Market, By Region:
1. How big is the global Highly Pathogenic PRRS Live Vaccine market?
2. What is the demand of the global Highly Pathogenic PRRS Live Vaccine market?
3. What is the year over year growth of the global Highly Pathogenic PRRS Live Vaccine market?
4. What is the production and production value of the global Highly Pathogenic PRRS Live Vaccine market?
5. Who are the key producers in the global Highly Pathogenic PRRS Live Vaccine market?
6. What are the growth factors driving the market demand?
Highly Pathogenic PRRS Live Vaccine is a modified live swine vaccine used for the prevention of highly pathogenic porcine reproductive and respiratory syndrome, also known as highly pathogenic porcine blue ear disease in China. Major commercial forms include monovalent vaccines based on JXA1-R, TJM-F92, GDr180, HuN4-F112 and related attenuated strains, as well as limited combination vaccines and heat-stabilized formulations containing a highly pathogenic PRRS component. Upstream inputs mainly include attenuated PRRSV seed strains, Marc-145 cells or other suitable cell substrates, culture media, serum or serum-free supplements, stabilizers, lyophilization protectants, diluents, glass vials, rubber stoppers, aluminum caps, labels and cold-chain packaging materials. Downstream customers mainly include integrated swine farming groups, breeding farms, commercial pig farms, veterinary drug distributors, animal disease control institutions and farm technical service providers. In 2025, global production capacity is estimated at around 286 million doses, with sales volume of about 207 million doses and an average ex-factory price of approximately USD 0.070–0.081 per dose; China accounts for the dominant share of both supply and demand, while overseas sales are limited and mainly related to export registration and use in nearby swine-producing markets. This is an approval- and batch-release-driven veterinary biologics segment with a relatively small single-product market size but strong disease-control relevance for pig farms. The estimated industry gross margin in 2025 is around 45%–60%, with leading producers benefiting from larger batch scale, established distribution channels and strain resources, while smaller suppliers face greater margin volatility due to batch size, channel discounts and cold-chain costs.
The current market is mainly supported by disease prevention demand in China's swine farming sector, with supply concentrated among companies that have veterinary biologics manufacturing qualifications, stable batch-release capabilities, mature cell culture processes and strong service capabilities for large-scale pig farms. This is not a globally widespread mass-market vaccine category, but a product segment closely linked to China's highly pathogenic porcine blue ear disease control system, veterinary drug registration framework and practical immunization programs in commercial swine production. Competition is not driven only by price and distribution channels, but also by product safety, batch consistency, field application experience, cold-chain assurance and the supplier's ability to support vaccination programs for farms with different herd health statuses. Demand shows clear structural differentiation. Large-scale pig farming groups and breeding farms place more emphasis on immunization safety, product consistency, strain relevance and long-term supply stability, so their purchasing decisions are generally more cautious. Commercial pig farms and small to medium-sized producers rely more on distributors, regional veterinary service networks and local disease pressure, and are relatively more price-sensitive. As swine farming becomes more consolidated, vaccine suppliers need to move beyond simple product sales and provide vaccination program design, antibody monitoring, herd stabilization management and integrated disease-control advice to strengthen customer stickiness and product value. Future development will focus more on safety improvement, process upgrading, combination vaccines and precision immunization. Traditional modified live vaccines still have advantages in immunogenicity, accumulated field experience and end-user acceptance, but their use will become more cautious in high-health-status farms and production systems pursuing PRRS elimination. Suspension culture can help improve production consistency and scale-up efficiency, heat-stabilized formulations can enhance storage and transportation stability, and combination vaccines can simplify immunization programs. As circulating PRRSV strains continue to evolve, companies also need stronger epidemiological monitoring and clinical validation capabilities to support product iteration and differentiated competition. The main growth drivers include the rising share of large-scale farming, continued investment in major swine disease control, more standardized veterinary vaccine regulation, improvement in farm biosecurity systems and stronger service capabilities among leading suppliers. Key constraints include hog price cycles affecting vaccination budgets, reduced use of live vaccines in some farms pursuing disease elimination, safety concerns related to modified live vaccines, uncertainty in protection caused by regional strain differences, and cost pressure from cold-chain logistics and batch quality control. Overall, this market is more stable and structurally adjusting than high-growth. Future growth will depend less on capacity expansion and more on product quality upgrades, customer concentration and stronger integrated service capabilities among leading companies.
This report studies the global Highly Pathogenic PRRS Live Vaccine production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Highly Pathogenic PRRS Live Vaccine and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Highly Pathogenic PRRS Live Vaccine that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Highly Pathogenic PRRS Live Vaccine total production and demand, 2021-2032, (K Dose)
Global Highly Pathogenic PRRS Live Vaccine total production value, 2021-2032, (USD Million)
Global Highly Pathogenic PRRS Live Vaccine production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (K Dose), (based on production site)
Global Highly Pathogenic PRRS Live Vaccine consumption by region & country, CAGR, 2021-2032 & (K Dose)
U.S. VS China: Highly Pathogenic PRRS Live Vaccine domestic production, consumption, key domestic manufacturers and share
Global Highly Pathogenic PRRS Live Vaccine production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (K Dose)
Global Highly Pathogenic PRRS Live Vaccine production by Type, production, value, CAGR, 2021-2032, (USD Million) & (K Dose)
Global Highly Pathogenic PRRS Live Vaccine production by Application, production, value, CAGR, 2021-2032, (USD Million) & (K Dose)
This report profiles key players in the global Highly Pathogenic PRRS Live Vaccine market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Dahuanong Animal Health, Zoetis, Jilin Teyan Biotechnology, Qingdao Yebio Bioengineering, Sinopharm Yangzhou Vac Biological Engineering, Pulike Biological Engineering, Guangdong WINSUN Bio-pharmaceutical, Sinovetah Biological Pharmaceutical, TECON Pharmaceutical, Harbin Veken Biotechnology, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Highly Pathogenic PRRS Live Vaccine market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Dose) and average price (US$/Dose) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Highly Pathogenic PRRS Live Vaccine Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- JXA1-R Strain Live Vaccine
- TJM-F92 Strain Live Vaccine
- GDr180 Strain Live Vaccine
- Others
- Monovalent Live Vaccine
- Combination Live Vaccine
- Small Pack (Below 20 Doses per Vial)
- Medium Pack (20–50 Doses per Vial)
- Large Pack (Above 50 Doses per Vial)
- Large-scale Integrated Pig Farming Groups
- Breeding and Multiplier Farms
- Animal Disease Control Institutions
- Others
- Dahuanong Animal Health
- Zoetis
- Jilin Teyan Biotechnology
- Qingdao Yebio Bioengineering
- Sinopharm Yangzhou Vac Biological Engineering
- Pulike Biological Engineering
- Guangdong WINSUN Bio-pharmaceutical
- Sinovetah Biological Pharmaceutical
- TECON Pharmaceutical
- Harbin Veken Biotechnology
- CAHIC
- Huapai Biotechnology Group
- Chengdu Shiji Biological Pharmaceutical
- Jilin Heyuan Biotechnology
1. How big is the global Highly Pathogenic PRRS Live Vaccine market?
2. What is the demand of the global Highly Pathogenic PRRS Live Vaccine market?
3. What is the year over year growth of the global Highly Pathogenic PRRS Live Vaccine market?
4. What is the production and production value of the global Highly Pathogenic PRRS Live Vaccine market?
5. Who are the key producers in the global Highly Pathogenic PRRS Live Vaccine market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Highly Pathogenic PRRS Live Vaccine Introduction
1.2 World Highly Pathogenic PRRS Live Vaccine Supply & Forecast
1.2.1 World Highly Pathogenic PRRS Live Vaccine Production Value (2021 & 2025 & 2032)
1.2.2 World Highly Pathogenic PRRS Live Vaccine Production (2021-2032)
1.2.3 World Highly Pathogenic PRRS Live Vaccine Pricing Trends (2021-2032)
1.3 World Highly Pathogenic PRRS Live Vaccine Production by Region (Based on Production Site)
1.3.1 World Highly Pathogenic PRRS Live Vaccine Production Value by Region (2021-2032)
1.3.2 World Highly Pathogenic PRRS Live Vaccine Production by Region (2021-2032)
1.3.3 World Highly Pathogenic PRRS Live Vaccine Average Price by Region (2021-2032)
1.3.4 North America Highly Pathogenic PRRS Live Vaccine Production (2021-2032)
1.3.5 China Highly Pathogenic PRRS Live Vaccine Production (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Highly Pathogenic PRRS Live Vaccine Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Highly Pathogenic PRRS Live Vaccine Major Market Trends
2 DEMAND SUMMARY
2.1 World Highly Pathogenic PRRS Live Vaccine Demand (2021-2032)
2.2 World Highly Pathogenic PRRS Live Vaccine Consumption by Region
2.2.1 World Highly Pathogenic PRRS Live Vaccine Consumption by Region (2021-2026)
2.2.2 World Highly Pathogenic PRRS Live Vaccine Consumption Forecast by Region (2027-2032)
2.3 United States Highly Pathogenic PRRS Live Vaccine Consumption (2021-2032)
2.4 China Highly Pathogenic PRRS Live Vaccine Consumption (2021-2032)
2.5 Europe Highly Pathogenic PRRS Live Vaccine Consumption (2021-2032)
2.6 Japan Highly Pathogenic PRRS Live Vaccine Consumption (2021-2032)
2.7 South Korea Highly Pathogenic PRRS Live Vaccine Consumption (2021-2032)
2.8 ASEAN Highly Pathogenic PRRS Live Vaccine Consumption (2021-2032)
2.9 India Highly Pathogenic PRRS Live Vaccine Consumption (2021-2032)
3 WORLD MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Highly Pathogenic PRRS Live Vaccine Production Value by Manufacturer (2021-2026)
3.2 World Highly Pathogenic PRRS Live Vaccine Production by Manufacturer (2021-2026)
3.3 World Highly Pathogenic PRRS Live Vaccine Average Price by Manufacturer (2021-2026)
3.4 Highly Pathogenic PRRS Live Vaccine Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Highly Pathogenic PRRS Live Vaccine Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Highly Pathogenic PRRS Live Vaccine in 2025
3.5.3 Global Concentration Ratios (CR8) for Highly Pathogenic PRRS Live Vaccine in 2025
3.6 Highly Pathogenic PRRS Live Vaccine Market: Overall Company Footprint Analysis
3.6.1 Highly Pathogenic PRRS Live Vaccine Market: Region Footprint
3.6.2 Highly Pathogenic PRRS Live Vaccine Market: Company Product Type Footprint
3.6.3 Highly Pathogenic PRRS Live Vaccine Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Highly Pathogenic PRRS Live Vaccine Production Value Comparison
4.1.1 United States VS China: Highly Pathogenic PRRS Live Vaccine Production Value Comparison (2021 & 2025 & 2032)
4.1.2 United States VS China: Highly Pathogenic PRRS Live Vaccine Production Value Market Share Comparison (2021 & 2025 & 2032)
4.2 United States VS China: Highly Pathogenic PRRS Live Vaccine Production Comparison
4.2.1 United States VS China: Highly Pathogenic PRRS Live Vaccine Production Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Highly Pathogenic PRRS Live Vaccine Production Market Share Comparison (2021 & 2025 & 2032)
4.3 United States VS China: Highly Pathogenic PRRS Live Vaccine Consumption Comparison
4.3.1 United States VS China: Highly Pathogenic PRRS Live Vaccine Consumption Comparison (2021 & 2025 & 2032)
4.3.2 United States VS China: Highly Pathogenic PRRS Live Vaccine Consumption Market Share Comparison (2021 & 2025 & 2032)
4.4 United States Based Highly Pathogenic PRRS Live Vaccine Manufacturers and Market Share, 2021-2026
4.4.1 United States Based Highly Pathogenic PRRS Live Vaccine Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Highly Pathogenic PRRS Live Vaccine Production Value (2021-2026)
4.4.3 United States Based Manufacturers Highly Pathogenic PRRS Live Vaccine Production (2021-2026)
4.5 China Based Highly Pathogenic PRRS Live Vaccine Manufacturers and Market Share
4.5.1 China Based Highly Pathogenic PRRS Live Vaccine Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Highly Pathogenic PRRS Live Vaccine Production Value (2021-2026)
4.5.3 China Based Manufacturers Highly Pathogenic PRRS Live Vaccine Production (2021-2026)
4.6 Rest of World Based Highly Pathogenic PRRS Live Vaccine Manufacturers and Market Share, 2021-2026
4.6.1 Rest of World Based Highly Pathogenic PRRS Live Vaccine Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Highly Pathogenic PRRS Live Vaccine Production Value (2021-2026)
4.6.3 Rest of World Based Manufacturers Highly Pathogenic PRRS Live Vaccine Production (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Highly Pathogenic PRRS Live Vaccine Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 JXA1-R Strain Live Vaccine
5.2.2 TJM-F92 Strain Live Vaccine
5.2.3 GDr180 Strain Live Vaccine
5.2.4 Others
5.3 Market Segment by Type
5.3.1 World Highly Pathogenic PRRS Live Vaccine Production by Type (2021-2032)
5.3.2 World Highly Pathogenic PRRS Live Vaccine Production Value by Type (2021-2032)
5.3.3 World Highly Pathogenic PRRS Live Vaccine Average Price by Type (2021-2032)
6 MARKET ANALYSIS BY PRODUCT COMBINATION
6.1 World Highly Pathogenic PRRS Live Vaccine Market Size Overview by Product Combination: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Product Combination
6.2.1 Monovalent Live Vaccine
6.2.2 Combination Live Vaccine
6.3 Market Segment by Product Combination
6.3.1 World Highly Pathogenic PRRS Live Vaccine Production by Product Combination (2021-2032)
6.3.2 World Highly Pathogenic PRRS Live Vaccine Production Value by Product Combination (2021-2032)
6.3.3 World Highly Pathogenic PRRS Live Vaccine Average Price by Product Combination (2021-2032)
7 MARKET ANALYSIS BY DOSE PACK SIZE
7.1 World Highly Pathogenic PRRS Live Vaccine Market Size Overview by Dose Pack Size: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Dose Pack Size
7.2.1 Small Pack (Below 20 Doses per Vial)
7.2.2 Medium Pack (20–50 Doses per Vial)
7.2.3 Large Pack (Above 50 Doses per Vial)
7.3 Market Segment by Dose Pack Size
7.3.1 World Highly Pathogenic PRRS Live Vaccine Production by Dose Pack Size (2021-2032)
7.3.2 World Highly Pathogenic PRRS Live Vaccine Production Value by Dose Pack Size (2021-2032)
7.3.3 World Highly Pathogenic PRRS Live Vaccine Average Price by Dose Pack Size (2021-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Highly Pathogenic PRRS Live Vaccine Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Large-scale Integrated Pig Farming Groups
8.2.2 Breeding and Multiplier Farms
8.2.3 Animal Disease Control Institutions
8.2.4 Others
8.3 Market Segment by Application
8.3.1 World Highly Pathogenic PRRS Live Vaccine Production by Application (2021-2032)
8.3.2 World Highly Pathogenic PRRS Live Vaccine Production Value by Application (2021-2032)
8.3.3 World Highly Pathogenic PRRS Live Vaccine Average Price by Application (2021-2032)
9 COMPANY PROFILES
9.1 Dahuanong Animal Health
9.1.1 Dahuanong Animal Health Details
9.1.2 Dahuanong Animal Health Major Business
9.1.3 Dahuanong Animal Health Highly Pathogenic PRRS Live Vaccine Product and Services
9.1.4 Dahuanong Animal Health Highly Pathogenic PRRS Live Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.1.5 Dahuanong Animal Health Recent Developments/Updates
9.1.6 Dahuanong Animal Health Competitive Strengths & Weaknesses
9.2 Zoetis
9.2.1 Zoetis Details
9.2.2 Zoetis Major Business
9.2.3 Zoetis Highly Pathogenic PRRS Live Vaccine Product and Services
9.2.4 Zoetis Highly Pathogenic PRRS Live Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.2.5 Zoetis Recent Developments/Updates
9.2.6 Zoetis Competitive Strengths & Weaknesses
9.3 Jilin Teyan Biotechnology
9.3.1 Jilin Teyan Biotechnology Details
9.3.2 Jilin Teyan Biotechnology Major Business
9.3.3 Jilin Teyan Biotechnology Highly Pathogenic PRRS Live Vaccine Product and Services
9.3.4 Jilin Teyan Biotechnology Highly Pathogenic PRRS Live Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.3.5 Jilin Teyan Biotechnology Recent Developments/Updates
9.3.6 Jilin Teyan Biotechnology Competitive Strengths & Weaknesses
9.4 Qingdao Yebio Bioengineering
9.4.1 Qingdao Yebio Bioengineering Details
9.4.2 Qingdao Yebio Bioengineering Major Business
9.4.3 Qingdao Yebio Bioengineering Highly Pathogenic PRRS Live Vaccine Product and Services
9.4.4 Qingdao Yebio Bioengineering Highly Pathogenic PRRS Live Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.4.5 Qingdao Yebio Bioengineering Recent Developments/Updates
9.4.6 Qingdao Yebio Bioengineering Competitive Strengths & Weaknesses
9.5 Sinopharm Yangzhou Vac Biological Engineering
9.5.1 Sinopharm Yangzhou Vac Biological Engineering Details
9.5.2 Sinopharm Yangzhou Vac Biological Engineering Major Business
9.5.3 Sinopharm Yangzhou Vac Biological Engineering Highly Pathogenic PRRS Live Vaccine Product and Services
9.5.4 Sinopharm Yangzhou Vac Biological Engineering Highly Pathogenic PRRS Live Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.5.5 Sinopharm Yangzhou Vac Biological Engineering Recent Developments/Updates
9.5.6 Sinopharm Yangzhou Vac Biological Engineering Competitive Strengths & Weaknesses
9.6 Pulike Biological Engineering
9.6.1 Pulike Biological Engineering Details
9.6.2 Pulike Biological Engineering Major Business
9.6.3 Pulike Biological Engineering Highly Pathogenic PRRS Live Vaccine Product and Services
9.6.4 Pulike Biological Engineering Highly Pathogenic PRRS Live Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.6.5 Pulike Biological Engineering Recent Developments/Updates
9.6.6 Pulike Biological Engineering Competitive Strengths & Weaknesses
9.7 Guangdong WINSUN Bio-pharmaceutical
9.7.1 Guangdong WINSUN Bio-pharmaceutical Details
9.7.2 Guangdong WINSUN Bio-pharmaceutical Major Business
9.7.3 Guangdong WINSUN Bio-pharmaceutical Highly Pathogenic PRRS Live Vaccine Product and Services
9.7.4 Guangdong WINSUN Bio-pharmaceutical Highly Pathogenic PRRS Live Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.7.5 Guangdong WINSUN Bio-pharmaceutical Recent Developments/Updates
9.7.6 Guangdong WINSUN Bio-pharmaceutical Competitive Strengths & Weaknesses
9.8 Sinovetah Biological Pharmaceutical
9.8.1 Sinovetah Biological Pharmaceutical Details
9.8.2 Sinovetah Biological Pharmaceutical Major Business
9.8.3 Sinovetah Biological Pharmaceutical Highly Pathogenic PRRS Live Vaccine Product and Services
9.8.4 Sinovetah Biological Pharmaceutical Highly Pathogenic PRRS Live Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.8.5 Sinovetah Biological Pharmaceutical Recent Developments/Updates
9.8.6 Sinovetah Biological Pharmaceutical Competitive Strengths & Weaknesses
9.9 TECON Pharmaceutical
9.9.1 TECON Pharmaceutical Details
9.9.2 TECON Pharmaceutical Major Business
9.9.3 TECON Pharmaceutical Highly Pathogenic PRRS Live Vaccine Product and Services
9.9.4 TECON Pharmaceutical Highly Pathogenic PRRS Live Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.9.5 TECON Pharmaceutical Recent Developments/Updates
9.9.6 TECON Pharmaceutical Competitive Strengths & Weaknesses
9.10 Harbin Veken Biotechnology
9.10.1 Harbin Veken Biotechnology Details
9.10.2 Harbin Veken Biotechnology Major Business
9.10.3 Harbin Veken Biotechnology Highly Pathogenic PRRS Live Vaccine Product and Services
9.10.4 Harbin Veken Biotechnology Highly Pathogenic PRRS Live Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.10.5 Harbin Veken Biotechnology Recent Developments/Updates
9.10.6 Harbin Veken Biotechnology Competitive Strengths & Weaknesses
9.11 CAHIC
9.11.1 CAHIC Details
9.11.2 CAHIC Major Business
9.11.3 CAHIC Highly Pathogenic PRRS Live Vaccine Product and Services
9.11.4 CAHIC Highly Pathogenic PRRS Live Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.11.5 CAHIC Recent Developments/Updates
9.11.6 CAHIC Competitive Strengths & Weaknesses
9.12 Huapai Biotechnology Group
9.12.1 Huapai Biotechnology Group Details
9.12.2 Huapai Biotechnology Group Major Business
9.12.3 Huapai Biotechnology Group Highly Pathogenic PRRS Live Vaccine Product and Services
9.12.4 Huapai Biotechnology Group Highly Pathogenic PRRS Live Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.12.5 Huapai Biotechnology Group Recent Developments/Updates
9.12.6 Huapai Biotechnology Group Competitive Strengths & Weaknesses
9.13 Chengdu Shiji Biological Pharmaceutical
9.13.1 Chengdu Shiji Biological Pharmaceutical Details
9.13.2 Chengdu Shiji Biological Pharmaceutical Major Business
9.13.3 Chengdu Shiji Biological Pharmaceutical Highly Pathogenic PRRS Live Vaccine Product and Services
9.13.4 Chengdu Shiji Biological Pharmaceutical Highly Pathogenic PRRS Live Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.13.5 Chengdu Shiji Biological Pharmaceutical Recent Developments/Updates
9.13.6 Chengdu Shiji Biological Pharmaceutical Competitive Strengths & Weaknesses
9.14 Jilin Heyuan Biotechnology
9.14.1 Jilin Heyuan Biotechnology Details
9.14.2 Jilin Heyuan Biotechnology Major Business
9.14.3 Jilin Heyuan Biotechnology Highly Pathogenic PRRS Live Vaccine Product and Services
9.14.4 Jilin Heyuan Biotechnology Highly Pathogenic PRRS Live Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.14.5 Jilin Heyuan Biotechnology Recent Developments/Updates
9.14.6 Jilin Heyuan Biotechnology Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Highly Pathogenic PRRS Live Vaccine Industry Chain
10.2 Highly Pathogenic PRRS Live Vaccine Upstream Analysis
10.2.1 Highly Pathogenic PRRS Live Vaccine Core Raw Materials
10.2.2 Main Manufacturers of Highly Pathogenic PRRS Live Vaccine Core Raw Materials
10.3 Midstream Analysis
10.4 Downstream Analysis
10.5 Highly Pathogenic PRRS Live Vaccine Production Mode
10.6 Highly Pathogenic PRRS Live Vaccine Procurement Model
10.7 Highly Pathogenic PRRS Live Vaccine Industry Sales Model and Sales Channels
10.7.1 Highly Pathogenic PRRS Live Vaccine Sales Model
10.7.2 Highly Pathogenic PRRS Live Vaccine Typical Distributors
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
1.1 Highly Pathogenic PRRS Live Vaccine Introduction
1.2 World Highly Pathogenic PRRS Live Vaccine Supply & Forecast
1.2.1 World Highly Pathogenic PRRS Live Vaccine Production Value (2021 & 2025 & 2032)
1.2.2 World Highly Pathogenic PRRS Live Vaccine Production (2021-2032)
1.2.3 World Highly Pathogenic PRRS Live Vaccine Pricing Trends (2021-2032)
1.3 World Highly Pathogenic PRRS Live Vaccine Production by Region (Based on Production Site)
1.3.1 World Highly Pathogenic PRRS Live Vaccine Production Value by Region (2021-2032)
1.3.2 World Highly Pathogenic PRRS Live Vaccine Production by Region (2021-2032)
1.3.3 World Highly Pathogenic PRRS Live Vaccine Average Price by Region (2021-2032)
1.3.4 North America Highly Pathogenic PRRS Live Vaccine Production (2021-2032)
1.3.5 China Highly Pathogenic PRRS Live Vaccine Production (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Highly Pathogenic PRRS Live Vaccine Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Highly Pathogenic PRRS Live Vaccine Major Market Trends
2 DEMAND SUMMARY
2.1 World Highly Pathogenic PRRS Live Vaccine Demand (2021-2032)
2.2 World Highly Pathogenic PRRS Live Vaccine Consumption by Region
2.2.1 World Highly Pathogenic PRRS Live Vaccine Consumption by Region (2021-2026)
2.2.2 World Highly Pathogenic PRRS Live Vaccine Consumption Forecast by Region (2027-2032)
2.3 United States Highly Pathogenic PRRS Live Vaccine Consumption (2021-2032)
2.4 China Highly Pathogenic PRRS Live Vaccine Consumption (2021-2032)
2.5 Europe Highly Pathogenic PRRS Live Vaccine Consumption (2021-2032)
2.6 Japan Highly Pathogenic PRRS Live Vaccine Consumption (2021-2032)
2.7 South Korea Highly Pathogenic PRRS Live Vaccine Consumption (2021-2032)
2.8 ASEAN Highly Pathogenic PRRS Live Vaccine Consumption (2021-2032)
2.9 India Highly Pathogenic PRRS Live Vaccine Consumption (2021-2032)
3 WORLD MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Highly Pathogenic PRRS Live Vaccine Production Value by Manufacturer (2021-2026)
3.2 World Highly Pathogenic PRRS Live Vaccine Production by Manufacturer (2021-2026)
3.3 World Highly Pathogenic PRRS Live Vaccine Average Price by Manufacturer (2021-2026)
3.4 Highly Pathogenic PRRS Live Vaccine Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Highly Pathogenic PRRS Live Vaccine Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Highly Pathogenic PRRS Live Vaccine in 2025
3.5.3 Global Concentration Ratios (CR8) for Highly Pathogenic PRRS Live Vaccine in 2025
3.6 Highly Pathogenic PRRS Live Vaccine Market: Overall Company Footprint Analysis
3.6.1 Highly Pathogenic PRRS Live Vaccine Market: Region Footprint
3.6.2 Highly Pathogenic PRRS Live Vaccine Market: Company Product Type Footprint
3.6.3 Highly Pathogenic PRRS Live Vaccine Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Highly Pathogenic PRRS Live Vaccine Production Value Comparison
4.1.1 United States VS China: Highly Pathogenic PRRS Live Vaccine Production Value Comparison (2021 & 2025 & 2032)
4.1.2 United States VS China: Highly Pathogenic PRRS Live Vaccine Production Value Market Share Comparison (2021 & 2025 & 2032)
4.2 United States VS China: Highly Pathogenic PRRS Live Vaccine Production Comparison
4.2.1 United States VS China: Highly Pathogenic PRRS Live Vaccine Production Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Highly Pathogenic PRRS Live Vaccine Production Market Share Comparison (2021 & 2025 & 2032)
4.3 United States VS China: Highly Pathogenic PRRS Live Vaccine Consumption Comparison
4.3.1 United States VS China: Highly Pathogenic PRRS Live Vaccine Consumption Comparison (2021 & 2025 & 2032)
4.3.2 United States VS China: Highly Pathogenic PRRS Live Vaccine Consumption Market Share Comparison (2021 & 2025 & 2032)
4.4 United States Based Highly Pathogenic PRRS Live Vaccine Manufacturers and Market Share, 2021-2026
4.4.1 United States Based Highly Pathogenic PRRS Live Vaccine Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Highly Pathogenic PRRS Live Vaccine Production Value (2021-2026)
4.4.3 United States Based Manufacturers Highly Pathogenic PRRS Live Vaccine Production (2021-2026)
4.5 China Based Highly Pathogenic PRRS Live Vaccine Manufacturers and Market Share
4.5.1 China Based Highly Pathogenic PRRS Live Vaccine Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Highly Pathogenic PRRS Live Vaccine Production Value (2021-2026)
4.5.3 China Based Manufacturers Highly Pathogenic PRRS Live Vaccine Production (2021-2026)
4.6 Rest of World Based Highly Pathogenic PRRS Live Vaccine Manufacturers and Market Share, 2021-2026
4.6.1 Rest of World Based Highly Pathogenic PRRS Live Vaccine Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Highly Pathogenic PRRS Live Vaccine Production Value (2021-2026)
4.6.3 Rest of World Based Manufacturers Highly Pathogenic PRRS Live Vaccine Production (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Highly Pathogenic PRRS Live Vaccine Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 JXA1-R Strain Live Vaccine
5.2.2 TJM-F92 Strain Live Vaccine
5.2.3 GDr180 Strain Live Vaccine
5.2.4 Others
5.3 Market Segment by Type
5.3.1 World Highly Pathogenic PRRS Live Vaccine Production by Type (2021-2032)
5.3.2 World Highly Pathogenic PRRS Live Vaccine Production Value by Type (2021-2032)
5.3.3 World Highly Pathogenic PRRS Live Vaccine Average Price by Type (2021-2032)
6 MARKET ANALYSIS BY PRODUCT COMBINATION
6.1 World Highly Pathogenic PRRS Live Vaccine Market Size Overview by Product Combination: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Product Combination
6.2.1 Monovalent Live Vaccine
6.2.2 Combination Live Vaccine
6.3 Market Segment by Product Combination
6.3.1 World Highly Pathogenic PRRS Live Vaccine Production by Product Combination (2021-2032)
6.3.2 World Highly Pathogenic PRRS Live Vaccine Production Value by Product Combination (2021-2032)
6.3.3 World Highly Pathogenic PRRS Live Vaccine Average Price by Product Combination (2021-2032)
7 MARKET ANALYSIS BY DOSE PACK SIZE
7.1 World Highly Pathogenic PRRS Live Vaccine Market Size Overview by Dose Pack Size: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Dose Pack Size
7.2.1 Small Pack (Below 20 Doses per Vial)
7.2.2 Medium Pack (20–50 Doses per Vial)
7.2.3 Large Pack (Above 50 Doses per Vial)
7.3 Market Segment by Dose Pack Size
7.3.1 World Highly Pathogenic PRRS Live Vaccine Production by Dose Pack Size (2021-2032)
7.3.2 World Highly Pathogenic PRRS Live Vaccine Production Value by Dose Pack Size (2021-2032)
7.3.3 World Highly Pathogenic PRRS Live Vaccine Average Price by Dose Pack Size (2021-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Highly Pathogenic PRRS Live Vaccine Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Large-scale Integrated Pig Farming Groups
8.2.2 Breeding and Multiplier Farms
8.2.3 Animal Disease Control Institutions
8.2.4 Others
8.3 Market Segment by Application
8.3.1 World Highly Pathogenic PRRS Live Vaccine Production by Application (2021-2032)
8.3.2 World Highly Pathogenic PRRS Live Vaccine Production Value by Application (2021-2032)
8.3.3 World Highly Pathogenic PRRS Live Vaccine Average Price by Application (2021-2032)
9 COMPANY PROFILES
9.1 Dahuanong Animal Health
9.1.1 Dahuanong Animal Health Details
9.1.2 Dahuanong Animal Health Major Business
9.1.3 Dahuanong Animal Health Highly Pathogenic PRRS Live Vaccine Product and Services
9.1.4 Dahuanong Animal Health Highly Pathogenic PRRS Live Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.1.5 Dahuanong Animal Health Recent Developments/Updates
9.1.6 Dahuanong Animal Health Competitive Strengths & Weaknesses
9.2 Zoetis
9.2.1 Zoetis Details
9.2.2 Zoetis Major Business
9.2.3 Zoetis Highly Pathogenic PRRS Live Vaccine Product and Services
9.2.4 Zoetis Highly Pathogenic PRRS Live Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.2.5 Zoetis Recent Developments/Updates
9.2.6 Zoetis Competitive Strengths & Weaknesses
9.3 Jilin Teyan Biotechnology
9.3.1 Jilin Teyan Biotechnology Details
9.3.2 Jilin Teyan Biotechnology Major Business
9.3.3 Jilin Teyan Biotechnology Highly Pathogenic PRRS Live Vaccine Product and Services
9.3.4 Jilin Teyan Biotechnology Highly Pathogenic PRRS Live Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.3.5 Jilin Teyan Biotechnology Recent Developments/Updates
9.3.6 Jilin Teyan Biotechnology Competitive Strengths & Weaknesses
9.4 Qingdao Yebio Bioengineering
9.4.1 Qingdao Yebio Bioengineering Details
9.4.2 Qingdao Yebio Bioengineering Major Business
9.4.3 Qingdao Yebio Bioengineering Highly Pathogenic PRRS Live Vaccine Product and Services
9.4.4 Qingdao Yebio Bioengineering Highly Pathogenic PRRS Live Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.4.5 Qingdao Yebio Bioengineering Recent Developments/Updates
9.4.6 Qingdao Yebio Bioengineering Competitive Strengths & Weaknesses
9.5 Sinopharm Yangzhou Vac Biological Engineering
9.5.1 Sinopharm Yangzhou Vac Biological Engineering Details
9.5.2 Sinopharm Yangzhou Vac Biological Engineering Major Business
9.5.3 Sinopharm Yangzhou Vac Biological Engineering Highly Pathogenic PRRS Live Vaccine Product and Services
9.5.4 Sinopharm Yangzhou Vac Biological Engineering Highly Pathogenic PRRS Live Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.5.5 Sinopharm Yangzhou Vac Biological Engineering Recent Developments/Updates
9.5.6 Sinopharm Yangzhou Vac Biological Engineering Competitive Strengths & Weaknesses
9.6 Pulike Biological Engineering
9.6.1 Pulike Biological Engineering Details
9.6.2 Pulike Biological Engineering Major Business
9.6.3 Pulike Biological Engineering Highly Pathogenic PRRS Live Vaccine Product and Services
9.6.4 Pulike Biological Engineering Highly Pathogenic PRRS Live Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.6.5 Pulike Biological Engineering Recent Developments/Updates
9.6.6 Pulike Biological Engineering Competitive Strengths & Weaknesses
9.7 Guangdong WINSUN Bio-pharmaceutical
9.7.1 Guangdong WINSUN Bio-pharmaceutical Details
9.7.2 Guangdong WINSUN Bio-pharmaceutical Major Business
9.7.3 Guangdong WINSUN Bio-pharmaceutical Highly Pathogenic PRRS Live Vaccine Product and Services
9.7.4 Guangdong WINSUN Bio-pharmaceutical Highly Pathogenic PRRS Live Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.7.5 Guangdong WINSUN Bio-pharmaceutical Recent Developments/Updates
9.7.6 Guangdong WINSUN Bio-pharmaceutical Competitive Strengths & Weaknesses
9.8 Sinovetah Biological Pharmaceutical
9.8.1 Sinovetah Biological Pharmaceutical Details
9.8.2 Sinovetah Biological Pharmaceutical Major Business
9.8.3 Sinovetah Biological Pharmaceutical Highly Pathogenic PRRS Live Vaccine Product and Services
9.8.4 Sinovetah Biological Pharmaceutical Highly Pathogenic PRRS Live Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.8.5 Sinovetah Biological Pharmaceutical Recent Developments/Updates
9.8.6 Sinovetah Biological Pharmaceutical Competitive Strengths & Weaknesses
9.9 TECON Pharmaceutical
9.9.1 TECON Pharmaceutical Details
9.9.2 TECON Pharmaceutical Major Business
9.9.3 TECON Pharmaceutical Highly Pathogenic PRRS Live Vaccine Product and Services
9.9.4 TECON Pharmaceutical Highly Pathogenic PRRS Live Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.9.5 TECON Pharmaceutical Recent Developments/Updates
9.9.6 TECON Pharmaceutical Competitive Strengths & Weaknesses
9.10 Harbin Veken Biotechnology
9.10.1 Harbin Veken Biotechnology Details
9.10.2 Harbin Veken Biotechnology Major Business
9.10.3 Harbin Veken Biotechnology Highly Pathogenic PRRS Live Vaccine Product and Services
9.10.4 Harbin Veken Biotechnology Highly Pathogenic PRRS Live Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.10.5 Harbin Veken Biotechnology Recent Developments/Updates
9.10.6 Harbin Veken Biotechnology Competitive Strengths & Weaknesses
9.11 CAHIC
9.11.1 CAHIC Details
9.11.2 CAHIC Major Business
9.11.3 CAHIC Highly Pathogenic PRRS Live Vaccine Product and Services
9.11.4 CAHIC Highly Pathogenic PRRS Live Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.11.5 CAHIC Recent Developments/Updates
9.11.6 CAHIC Competitive Strengths & Weaknesses
9.12 Huapai Biotechnology Group
9.12.1 Huapai Biotechnology Group Details
9.12.2 Huapai Biotechnology Group Major Business
9.12.3 Huapai Biotechnology Group Highly Pathogenic PRRS Live Vaccine Product and Services
9.12.4 Huapai Biotechnology Group Highly Pathogenic PRRS Live Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.12.5 Huapai Biotechnology Group Recent Developments/Updates
9.12.6 Huapai Biotechnology Group Competitive Strengths & Weaknesses
9.13 Chengdu Shiji Biological Pharmaceutical
9.13.1 Chengdu Shiji Biological Pharmaceutical Details
9.13.2 Chengdu Shiji Biological Pharmaceutical Major Business
9.13.3 Chengdu Shiji Biological Pharmaceutical Highly Pathogenic PRRS Live Vaccine Product and Services
9.13.4 Chengdu Shiji Biological Pharmaceutical Highly Pathogenic PRRS Live Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.13.5 Chengdu Shiji Biological Pharmaceutical Recent Developments/Updates
9.13.6 Chengdu Shiji Biological Pharmaceutical Competitive Strengths & Weaknesses
9.14 Jilin Heyuan Biotechnology
9.14.1 Jilin Heyuan Biotechnology Details
9.14.2 Jilin Heyuan Biotechnology Major Business
9.14.3 Jilin Heyuan Biotechnology Highly Pathogenic PRRS Live Vaccine Product and Services
9.14.4 Jilin Heyuan Biotechnology Highly Pathogenic PRRS Live Vaccine Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.14.5 Jilin Heyuan Biotechnology Recent Developments/Updates
9.14.6 Jilin Heyuan Biotechnology Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Highly Pathogenic PRRS Live Vaccine Industry Chain
10.2 Highly Pathogenic PRRS Live Vaccine Upstream Analysis
10.2.1 Highly Pathogenic PRRS Live Vaccine Core Raw Materials
10.2.2 Main Manufacturers of Highly Pathogenic PRRS Live Vaccine Core Raw Materials
10.3 Midstream Analysis
10.4 Downstream Analysis
10.5 Highly Pathogenic PRRS Live Vaccine Production Mode
10.6 Highly Pathogenic PRRS Live Vaccine Procurement Model
10.7 Highly Pathogenic PRRS Live Vaccine Industry Sales Model and Sales Channels
10.7.1 Highly Pathogenic PRRS Live Vaccine Sales Model
10.7.2 Highly Pathogenic PRRS Live Vaccine Typical Distributors
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
LIST OF TABLES
Table 1. World Highly Pathogenic PRRS Live Vaccine Production Value by Region (2021, 2025 and 2032) & (USD Million)
Table 2. World Highly Pathogenic PRRS Live Vaccine Production Value by Region (2021-2026) & (USD Million)
Table 3. World Highly Pathogenic PRRS Live Vaccine Production Value by Region (2027-2032) & (USD Million)
Table 4. World Highly Pathogenic PRRS Live Vaccine Production Value Market Share by Region (2021-2026)
Table 5. World Highly Pathogenic PRRS Live Vaccine Production Value Market Share by Region (2027-2032)
Table 6. World Highly Pathogenic PRRS Live Vaccine Production by Region (2021-2026) & (K Dose)
Table 7. World Highly Pathogenic PRRS Live Vaccine Production by Region (2027-2032) & (K Dose)
Table 8. World Highly Pathogenic PRRS Live Vaccine Production Market Share by Region (2021-2026)
Table 9. World Highly Pathogenic PRRS Live Vaccine Production Market Share by Region (2027-2032)
Table 10. World Highly Pathogenic PRRS Live Vaccine Average Price by Region (2021-2026) & (US$/Dose)
Table 11. World Highly Pathogenic PRRS Live Vaccine Average Price by Region (2027-2032) & (US$/Dose)
Table 12. Highly Pathogenic PRRS Live Vaccine Major Market Trends
Table 13. World Highly Pathogenic PRRS Live Vaccine Consumption Growth Rate Forecast by Region (2021 & 2025 & 2032) & (K Dose)
Table 14. World Highly Pathogenic PRRS Live Vaccine Consumption by Region (2021-2026) & (K Dose)
Table 15. World Highly Pathogenic PRRS Live Vaccine Consumption Forecast by Region (2027-2032) & (K Dose)
Table 16. World Highly Pathogenic PRRS Live Vaccine Production Value by Manufacturer (2021-2026) & (USD Million)
Table 17. Production Value Market Share of Key Highly Pathogenic PRRS Live Vaccine Producers in 2025
Table 18. World Highly Pathogenic PRRS Live Vaccine Production by Manufacturer (2021-2026) & (K Dose)
Table 19. Production Market Share of Key Highly Pathogenic PRRS Live Vaccine Producers in 2025
Table 20. World Highly Pathogenic PRRS Live Vaccine Average Price by Manufacturer (2021-2026) & (US$/Dose)
Table 21. Global Highly Pathogenic PRRS Live Vaccine Company Evaluation Quadrant
Table 22. World Highly Pathogenic PRRS Live Vaccine Industry Rank of Major Manufacturers, Based on Production Value in 2025
Table 23. Head Office and Highly Pathogenic PRRS Live Vaccine Production Site of Key Manufacturer
Table 24. Highly Pathogenic PRRS Live Vaccine Market: Company Product Type Footprint
Table 25. Highly Pathogenic PRRS Live Vaccine Market: Company Product Application Footprint
Table 26. Highly Pathogenic PRRS Live Vaccine Competitive Factors
Table 27. Highly Pathogenic PRRS Live Vaccine New Entrant and Capacity Expansion Plans
Table 28. Highly Pathogenic PRRS Live Vaccine Mergers & Acquisitions Activity
Table 29. United States VS China Highly Pathogenic PRRS Live Vaccine Production Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 30. United States VS China Highly Pathogenic PRRS Live Vaccine Production Comparison, (2021 & 2025 & 2032) & (K Dose)
Table 31. United States VS China Highly Pathogenic PRRS Live Vaccine Consumption Comparison, (2021 & 2025 & 2032) & (K Dose)
Table 32. United States Based Highly Pathogenic PRRS Live Vaccine Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Highly Pathogenic PRRS Live Vaccine Production Value, (2021-2026) & (USD Million)
Table 34. United States Based Manufacturers Highly Pathogenic PRRS Live Vaccine Production Value Market Share (2021-2026)
Table 35. United States Based Manufacturers Highly Pathogenic PRRS Live Vaccine Production (2021-2026) & (K Dose)
Table 36. United States Based Manufacturers Highly Pathogenic PRRS Live Vaccine Production Market Share (2021-2026)
Table 37. China Based Highly Pathogenic PRRS Live Vaccine Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Highly Pathogenic PRRS Live Vaccine Production Value, (2021-2026) & (USD Million)
Table 39. China Based Manufacturers Highly Pathogenic PRRS Live Vaccine Production Value Market Share (2021-2026)
Table 40. China Based Manufacturers Highly Pathogenic PRRS Live Vaccine Production, (2021-2026) & (K Dose)
Table 41. China Based Manufacturers Highly Pathogenic PRRS Live Vaccine Production Market Share (2021-2026)
Table 42. Rest of World Based Highly Pathogenic PRRS Live Vaccine Manufacturers, Headquarters and Production Site (State, Country)
Table 43. Rest of World Based Manufacturers Highly Pathogenic PRRS Live Vaccine Production Value, (2021-2026) & (USD Million)
Table 44. Rest of World Based Manufacturers Highly Pathogenic PRRS Live Vaccine Production Value Market Share (2021-2026)
Table 45. Rest of World Based Manufacturers Highly Pathogenic PRRS Live Vaccine Production, (2021-2026) & (K Dose)
Table 46. Rest of World Based Manufacturers Highly Pathogenic PRRS Live Vaccine Production Market Share (2021-2026)
Table 47. World Highly Pathogenic PRRS Live Vaccine Production Value by Type, (USD Million), 2021 & 2025 & 2032
Table 48. World Highly Pathogenic PRRS Live Vaccine Production by Type (2021-2026) & (K Dose)
Table 49. World Highly Pathogenic PRRS Live Vaccine Production by Type (2027-2032) & (K Dose)
Table 50. World Highly Pathogenic PRRS Live Vaccine Production Value by Type (2021-2026) & (USD Million)
Table 51. World Highly Pathogenic PRRS Live Vaccine Production Value by Type (2027-2032) & (USD Million)
Table 52. World Highly Pathogenic PRRS Live Vaccine Average Price by Type (2021-2026) & (US$/Dose)
Table 53. World Highly Pathogenic PRRS Live Vaccine Average Price by Type (2027-2032) & (US$/Dose)
Table 54. World Highly Pathogenic PRRS Live Vaccine Production Value by Product Combination, (USD Million), 2021 & 2025 & 2032
Table 55. World Highly Pathogenic PRRS Live Vaccine Production by Product Combination (2021-2026) & (K Dose)
Table 56. World Highly Pathogenic PRRS Live Vaccine Production by Product Combination (2027-2032) & (K Dose)
Table 57. World Highly Pathogenic PRRS Live Vaccine Production Value by Product Combination (2021-2026) & (USD Million)
Table 58. World Highly Pathogenic PRRS Live Vaccine Production Value by Product Combination (2027-2032) & (USD Million)
Table 59. World Highly Pathogenic PRRS Live Vaccine Average Price by Product Combination (2021-2026) & (US$/Dose)
Table 60. World Highly Pathogenic PRRS Live Vaccine Average Price by Product Combination (2027-2032) & (US$/Dose)
Table 61. World Highly Pathogenic PRRS Live Vaccine Production Value by Dose Pack Size, (USD Million), 2021 & 2025 & 2032
Table 62. World Highly Pathogenic PRRS Live Vaccine Production by Dose Pack Size (2021-2026) & (K Dose)
Table 63. World Highly Pathogenic PRRS Live Vaccine Production by Dose Pack Size (2027-2032) & (K Dose)
Table 64. World Highly Pathogenic PRRS Live Vaccine Production Value by Dose Pack Size (2021-2026) & (USD Million)
Table 65. World Highly Pathogenic PRRS Live Vaccine Production Value by Dose Pack Size (2027-2032) & (USD Million)
Table 66. World Highly Pathogenic PRRS Live Vaccine Average Price by Dose Pack Size (2021-2026) & (US$/Dose)
Table 67. World Highly Pathogenic PRRS Live Vaccine Average Price by Dose Pack Size (2027-2032) & (US$/Dose)
Table 68. World Highly Pathogenic PRRS Live Vaccine Production Value by Application, (USD Million), 2021 & 2025 & 2032
Table 69. World Highly Pathogenic PRRS Live Vaccine Production by Application (2021-2026) & (K Dose)
Table 70. World Highly Pathogenic PRRS Live Vaccine Production by Application (2027-2032) & (K Dose)
Table 71. World Highly Pathogenic PRRS Live Vaccine Production Value by Application (2021-2026) & (USD Million)
Table 72. World Highly Pathogenic PRRS Live Vaccine Production Value by Application (2027-2032) & (USD Million)
Table 73. World Highly Pathogenic PRRS Live Vaccine Average Price by Application (2021-2026) & (US$/Dose)
Table 74. World Highly Pathogenic PRRS Live Vaccine Average Price by Application (2027-2032) & (US$/Dose)
Table 75. Dahuanong Animal Health Basic Information, Manufacturing Base and Competitors
Table 76. Dahuanong Animal Health Major Business
Table 77. Dahuanong Animal Health Highly Pathogenic PRRS Live Vaccine Product and Services
Table 78. Dahuanong Animal Health Highly Pathogenic PRRS Live Vaccine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 79. Dahuanong Animal Health Recent Developments/Updates
Table 80. Dahuanong Animal Health Competitive Strengths & Weaknesses
Table 81. Zoetis Basic Information, Manufacturing Base and Competitors
Table 82. Zoetis Major Business
Table 83. Zoetis Highly Pathogenic PRRS Live Vaccine Product and Services
Table 84. Zoetis Highly Pathogenic PRRS Live Vaccine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 85. Zoetis Recent Developments/Updates
Table 86. Zoetis Competitive Strengths & Weaknesses
Table 87. Jilin Teyan Biotechnology Basic Information, Manufacturing Base and Competitors
Table 88. Jilin Teyan Biotechnology Major Business
Table 89. Jilin Teyan Biotechnology Highly Pathogenic PRRS Live Vaccine Product and Services
Table 90. Jilin Teyan Biotechnology Highly Pathogenic PRRS Live Vaccine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 91. Jilin Teyan Biotechnology Recent Developments/Updates
Table 92. Jilin Teyan Biotechnology Competitive Strengths & Weaknesses
Table 93. Qingdao Yebio Bioengineering Basic Information, Manufacturing Base and Competitors
Table 94. Qingdao Yebio Bioengineering Major Business
Table 95. Qingdao Yebio Bioengineering Highly Pathogenic PRRS Live Vaccine Product and Services
Table 96. Qingdao Yebio Bioengineering Highly Pathogenic PRRS Live Vaccine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 97. Qingdao Yebio Bioengineering Recent Developments/Updates
Table 98. Qingdao Yebio Bioengineering Competitive Strengths & Weaknesses
Table 99. Sinopharm Yangzhou Vac Biological Engineering Basic Information, Manufacturing Base and Competitors
Table 100. Sinopharm Yangzhou Vac Biological Engineering Major Business
Table 101. Sinopharm Yangzhou Vac Biological Engineering Highly Pathogenic PRRS Live Vaccine Product and Services
Table 102. Sinopharm Yangzhou Vac Biological Engineering Highly Pathogenic PRRS Live Vaccine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 103. Sinopharm Yangzhou Vac Biological Engineering Recent Developments/Updates
Table 104. Sinopharm Yangzhou Vac Biological Engineering Competitive Strengths & Weaknesses
Table 105. Pulike Biological Engineering Basic Information, Manufacturing Base and Competitors
Table 106. Pulike Biological Engineering Major Business
Table 107. Pulike Biological Engineering Highly Pathogenic PRRS Live Vaccine Product and Services
Table 108. Pulike Biological Engineering Highly Pathogenic PRRS Live Vaccine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 109. Pulike Biological Engineering Recent Developments/Updates
Table 110. Pulike Biological Engineering Competitive Strengths & Weaknesses
Table 111. Guangdong WINSUN Bio-pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 112. Guangdong WINSUN Bio-pharmaceutical Major Business
Table 113. Guangdong WINSUN Bio-pharmaceutical Highly Pathogenic PRRS Live Vaccine Product and Services
Table 114. Guangdong WINSUN Bio-pharmaceutical Highly Pathogenic PRRS Live Vaccine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 115. Guangdong WINSUN Bio-pharmaceutical Recent Developments/Updates
Table 116. Guangdong WINSUN Bio-pharmaceutical Competitive Strengths & Weaknesses
Table 117. Sinovetah Biological Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 118. Sinovetah Biological Pharmaceutical Major Business
Table 119. Sinovetah Biological Pharmaceutical Highly Pathogenic PRRS Live Vaccine Product and Services
Table 120. Sinovetah Biological Pharmaceutical Highly Pathogenic PRRS Live Vaccine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 121. Sinovetah Biological Pharmaceutical Recent Developments/Updates
Table 122. Sinovetah Biological Pharmaceutical Competitive Strengths & Weaknesses
Table 123. TECON Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 124. TECON Pharmaceutical Major Business
Table 125. TECON Pharmaceutical Highly Pathogenic PRRS Live Vaccine Product and Services
Table 126. TECON Pharmaceutical Highly Pathogenic PRRS Live Vaccine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 127. TECON Pharmaceutical Recent Developments/Updates
Table 128. TECON Pharmaceutical Competitive Strengths & Weaknesses
Table 129. Harbin Veken Biotechnology Basic Information, Manufacturing Base and Competitors
Table 130. Harbin Veken Biotechnology Major Business
Table 131. Harbin Veken Biotechnology Highly Pathogenic PRRS Live Vaccine Product and Services
Table 132. Harbin Veken Biotechnology Highly Pathogenic PRRS Live Vaccine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 133. Harbin Veken Biotechnology Recent Developments/Updates
Table 134. Harbin Veken Biotechnology Competitive Strengths & Weaknesses
Table 135. CAHIC Basic Information, Manufacturing Base and Competitors
Table 136. CAHIC Major Business
Table 137. CAHIC Highly Pathogenic PRRS Live Vaccine Product and Services
Table 138. CAHIC Highly Pathogenic PRRS Live Vaccine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 139. CAHIC Recent Developments/Updates
Table 140. CAHIC Competitive Strengths & Weaknesses
Table 141. Huapai Biotechnology Group Basic Information, Manufacturing Base and Competitors
Table 142. Huapai Biotechnology Group Major Business
Table 143. Huapai Biotechnology Group Highly Pathogenic PRRS Live Vaccine Product and Services
Table 144. Huapai Biotechnology Group Highly Pathogenic PRRS Live Vaccine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 145. Huapai Biotechnology Group Recent Developments/Updates
Table 146. Huapai Biotechnology Group Competitive Strengths & Weaknesses
Table 147. Chengdu Shiji Biological Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 148. Chengdu Shiji Biological Pharmaceutical Major Business
Table 149. Chengdu Shiji Biological Pharmaceutical Highly Pathogenic PRRS Live Vaccine Product and Services
Table 150. Chengdu Shiji Biological Pharmaceutical Highly Pathogenic PRRS Live Vaccine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 151. Chengdu Shiji Biological Pharmaceutical Recent Developments/Updates
Table 152. Chengdu Shiji Biological Pharmaceutical Competitive Strengths & Weaknesses
Table 153. Jilin Heyuan Biotechnology Basic Information, Manufacturing Base and Competitors
Table 154. Jilin Heyuan Biotechnology Major Business
Table 155. Jilin Heyuan Biotechnology Highly Pathogenic PRRS Live Vaccine Product and Services
Table 156. Jilin Heyuan Biotechnology Highly Pathogenic PRRS Live Vaccine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 157. Jilin Heyuan Biotechnology Recent Developments/Updates
Table 158. Jilin Heyuan Biotechnology Competitive Strengths & Weaknesses
Table 159. Global Key Players of Highly Pathogenic PRRS Live Vaccine Upstream (Raw Materials)
Table 160. Global Highly Pathogenic PRRS Live Vaccine Typical Customers
Table 161. Highly Pathogenic PRRS Live Vaccine Typical Distributors
Table 1. World Highly Pathogenic PRRS Live Vaccine Production Value by Region (2021, 2025 and 2032) & (USD Million)
Table 2. World Highly Pathogenic PRRS Live Vaccine Production Value by Region (2021-2026) & (USD Million)
Table 3. World Highly Pathogenic PRRS Live Vaccine Production Value by Region (2027-2032) & (USD Million)
Table 4. World Highly Pathogenic PRRS Live Vaccine Production Value Market Share by Region (2021-2026)
Table 5. World Highly Pathogenic PRRS Live Vaccine Production Value Market Share by Region (2027-2032)
Table 6. World Highly Pathogenic PRRS Live Vaccine Production by Region (2021-2026) & (K Dose)
Table 7. World Highly Pathogenic PRRS Live Vaccine Production by Region (2027-2032) & (K Dose)
Table 8. World Highly Pathogenic PRRS Live Vaccine Production Market Share by Region (2021-2026)
Table 9. World Highly Pathogenic PRRS Live Vaccine Production Market Share by Region (2027-2032)
Table 10. World Highly Pathogenic PRRS Live Vaccine Average Price by Region (2021-2026) & (US$/Dose)
Table 11. World Highly Pathogenic PRRS Live Vaccine Average Price by Region (2027-2032) & (US$/Dose)
Table 12. Highly Pathogenic PRRS Live Vaccine Major Market Trends
Table 13. World Highly Pathogenic PRRS Live Vaccine Consumption Growth Rate Forecast by Region (2021 & 2025 & 2032) & (K Dose)
Table 14. World Highly Pathogenic PRRS Live Vaccine Consumption by Region (2021-2026) & (K Dose)
Table 15. World Highly Pathogenic PRRS Live Vaccine Consumption Forecast by Region (2027-2032) & (K Dose)
Table 16. World Highly Pathogenic PRRS Live Vaccine Production Value by Manufacturer (2021-2026) & (USD Million)
Table 17. Production Value Market Share of Key Highly Pathogenic PRRS Live Vaccine Producers in 2025
Table 18. World Highly Pathogenic PRRS Live Vaccine Production by Manufacturer (2021-2026) & (K Dose)
Table 19. Production Market Share of Key Highly Pathogenic PRRS Live Vaccine Producers in 2025
Table 20. World Highly Pathogenic PRRS Live Vaccine Average Price by Manufacturer (2021-2026) & (US$/Dose)
Table 21. Global Highly Pathogenic PRRS Live Vaccine Company Evaluation Quadrant
Table 22. World Highly Pathogenic PRRS Live Vaccine Industry Rank of Major Manufacturers, Based on Production Value in 2025
Table 23. Head Office and Highly Pathogenic PRRS Live Vaccine Production Site of Key Manufacturer
Table 24. Highly Pathogenic PRRS Live Vaccine Market: Company Product Type Footprint
Table 25. Highly Pathogenic PRRS Live Vaccine Market: Company Product Application Footprint
Table 26. Highly Pathogenic PRRS Live Vaccine Competitive Factors
Table 27. Highly Pathogenic PRRS Live Vaccine New Entrant and Capacity Expansion Plans
Table 28. Highly Pathogenic PRRS Live Vaccine Mergers & Acquisitions Activity
Table 29. United States VS China Highly Pathogenic PRRS Live Vaccine Production Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 30. United States VS China Highly Pathogenic PRRS Live Vaccine Production Comparison, (2021 & 2025 & 2032) & (K Dose)
Table 31. United States VS China Highly Pathogenic PRRS Live Vaccine Consumption Comparison, (2021 & 2025 & 2032) & (K Dose)
Table 32. United States Based Highly Pathogenic PRRS Live Vaccine Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Highly Pathogenic PRRS Live Vaccine Production Value, (2021-2026) & (USD Million)
Table 34. United States Based Manufacturers Highly Pathogenic PRRS Live Vaccine Production Value Market Share (2021-2026)
Table 35. United States Based Manufacturers Highly Pathogenic PRRS Live Vaccine Production (2021-2026) & (K Dose)
Table 36. United States Based Manufacturers Highly Pathogenic PRRS Live Vaccine Production Market Share (2021-2026)
Table 37. China Based Highly Pathogenic PRRS Live Vaccine Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Highly Pathogenic PRRS Live Vaccine Production Value, (2021-2026) & (USD Million)
Table 39. China Based Manufacturers Highly Pathogenic PRRS Live Vaccine Production Value Market Share (2021-2026)
Table 40. China Based Manufacturers Highly Pathogenic PRRS Live Vaccine Production, (2021-2026) & (K Dose)
Table 41. China Based Manufacturers Highly Pathogenic PRRS Live Vaccine Production Market Share (2021-2026)
Table 42. Rest of World Based Highly Pathogenic PRRS Live Vaccine Manufacturers, Headquarters and Production Site (State, Country)
Table 43. Rest of World Based Manufacturers Highly Pathogenic PRRS Live Vaccine Production Value, (2021-2026) & (USD Million)
Table 44. Rest of World Based Manufacturers Highly Pathogenic PRRS Live Vaccine Production Value Market Share (2021-2026)
Table 45. Rest of World Based Manufacturers Highly Pathogenic PRRS Live Vaccine Production, (2021-2026) & (K Dose)
Table 46. Rest of World Based Manufacturers Highly Pathogenic PRRS Live Vaccine Production Market Share (2021-2026)
Table 47. World Highly Pathogenic PRRS Live Vaccine Production Value by Type, (USD Million), 2021 & 2025 & 2032
Table 48. World Highly Pathogenic PRRS Live Vaccine Production by Type (2021-2026) & (K Dose)
Table 49. World Highly Pathogenic PRRS Live Vaccine Production by Type (2027-2032) & (K Dose)
Table 50. World Highly Pathogenic PRRS Live Vaccine Production Value by Type (2021-2026) & (USD Million)
Table 51. World Highly Pathogenic PRRS Live Vaccine Production Value by Type (2027-2032) & (USD Million)
Table 52. World Highly Pathogenic PRRS Live Vaccine Average Price by Type (2021-2026) & (US$/Dose)
Table 53. World Highly Pathogenic PRRS Live Vaccine Average Price by Type (2027-2032) & (US$/Dose)
Table 54. World Highly Pathogenic PRRS Live Vaccine Production Value by Product Combination, (USD Million), 2021 & 2025 & 2032
Table 55. World Highly Pathogenic PRRS Live Vaccine Production by Product Combination (2021-2026) & (K Dose)
Table 56. World Highly Pathogenic PRRS Live Vaccine Production by Product Combination (2027-2032) & (K Dose)
Table 57. World Highly Pathogenic PRRS Live Vaccine Production Value by Product Combination (2021-2026) & (USD Million)
Table 58. World Highly Pathogenic PRRS Live Vaccine Production Value by Product Combination (2027-2032) & (USD Million)
Table 59. World Highly Pathogenic PRRS Live Vaccine Average Price by Product Combination (2021-2026) & (US$/Dose)
Table 60. World Highly Pathogenic PRRS Live Vaccine Average Price by Product Combination (2027-2032) & (US$/Dose)
Table 61. World Highly Pathogenic PRRS Live Vaccine Production Value by Dose Pack Size, (USD Million), 2021 & 2025 & 2032
Table 62. World Highly Pathogenic PRRS Live Vaccine Production by Dose Pack Size (2021-2026) & (K Dose)
Table 63. World Highly Pathogenic PRRS Live Vaccine Production by Dose Pack Size (2027-2032) & (K Dose)
Table 64. World Highly Pathogenic PRRS Live Vaccine Production Value by Dose Pack Size (2021-2026) & (USD Million)
Table 65. World Highly Pathogenic PRRS Live Vaccine Production Value by Dose Pack Size (2027-2032) & (USD Million)
Table 66. World Highly Pathogenic PRRS Live Vaccine Average Price by Dose Pack Size (2021-2026) & (US$/Dose)
Table 67. World Highly Pathogenic PRRS Live Vaccine Average Price by Dose Pack Size (2027-2032) & (US$/Dose)
Table 68. World Highly Pathogenic PRRS Live Vaccine Production Value by Application, (USD Million), 2021 & 2025 & 2032
Table 69. World Highly Pathogenic PRRS Live Vaccine Production by Application (2021-2026) & (K Dose)
Table 70. World Highly Pathogenic PRRS Live Vaccine Production by Application (2027-2032) & (K Dose)
Table 71. World Highly Pathogenic PRRS Live Vaccine Production Value by Application (2021-2026) & (USD Million)
Table 72. World Highly Pathogenic PRRS Live Vaccine Production Value by Application (2027-2032) & (USD Million)
Table 73. World Highly Pathogenic PRRS Live Vaccine Average Price by Application (2021-2026) & (US$/Dose)
Table 74. World Highly Pathogenic PRRS Live Vaccine Average Price by Application (2027-2032) & (US$/Dose)
Table 75. Dahuanong Animal Health Basic Information, Manufacturing Base and Competitors
Table 76. Dahuanong Animal Health Major Business
Table 77. Dahuanong Animal Health Highly Pathogenic PRRS Live Vaccine Product and Services
Table 78. Dahuanong Animal Health Highly Pathogenic PRRS Live Vaccine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 79. Dahuanong Animal Health Recent Developments/Updates
Table 80. Dahuanong Animal Health Competitive Strengths & Weaknesses
Table 81. Zoetis Basic Information, Manufacturing Base and Competitors
Table 82. Zoetis Major Business
Table 83. Zoetis Highly Pathogenic PRRS Live Vaccine Product and Services
Table 84. Zoetis Highly Pathogenic PRRS Live Vaccine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 85. Zoetis Recent Developments/Updates
Table 86. Zoetis Competitive Strengths & Weaknesses
Table 87. Jilin Teyan Biotechnology Basic Information, Manufacturing Base and Competitors
Table 88. Jilin Teyan Biotechnology Major Business
Table 89. Jilin Teyan Biotechnology Highly Pathogenic PRRS Live Vaccine Product and Services
Table 90. Jilin Teyan Biotechnology Highly Pathogenic PRRS Live Vaccine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 91. Jilin Teyan Biotechnology Recent Developments/Updates
Table 92. Jilin Teyan Biotechnology Competitive Strengths & Weaknesses
Table 93. Qingdao Yebio Bioengineering Basic Information, Manufacturing Base and Competitors
Table 94. Qingdao Yebio Bioengineering Major Business
Table 95. Qingdao Yebio Bioengineering Highly Pathogenic PRRS Live Vaccine Product and Services
Table 96. Qingdao Yebio Bioengineering Highly Pathogenic PRRS Live Vaccine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 97. Qingdao Yebio Bioengineering Recent Developments/Updates
Table 98. Qingdao Yebio Bioengineering Competitive Strengths & Weaknesses
Table 99. Sinopharm Yangzhou Vac Biological Engineering Basic Information, Manufacturing Base and Competitors
Table 100. Sinopharm Yangzhou Vac Biological Engineering Major Business
Table 101. Sinopharm Yangzhou Vac Biological Engineering Highly Pathogenic PRRS Live Vaccine Product and Services
Table 102. Sinopharm Yangzhou Vac Biological Engineering Highly Pathogenic PRRS Live Vaccine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 103. Sinopharm Yangzhou Vac Biological Engineering Recent Developments/Updates
Table 104. Sinopharm Yangzhou Vac Biological Engineering Competitive Strengths & Weaknesses
Table 105. Pulike Biological Engineering Basic Information, Manufacturing Base and Competitors
Table 106. Pulike Biological Engineering Major Business
Table 107. Pulike Biological Engineering Highly Pathogenic PRRS Live Vaccine Product and Services
Table 108. Pulike Biological Engineering Highly Pathogenic PRRS Live Vaccine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 109. Pulike Biological Engineering Recent Developments/Updates
Table 110. Pulike Biological Engineering Competitive Strengths & Weaknesses
Table 111. Guangdong WINSUN Bio-pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 112. Guangdong WINSUN Bio-pharmaceutical Major Business
Table 113. Guangdong WINSUN Bio-pharmaceutical Highly Pathogenic PRRS Live Vaccine Product and Services
Table 114. Guangdong WINSUN Bio-pharmaceutical Highly Pathogenic PRRS Live Vaccine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 115. Guangdong WINSUN Bio-pharmaceutical Recent Developments/Updates
Table 116. Guangdong WINSUN Bio-pharmaceutical Competitive Strengths & Weaknesses
Table 117. Sinovetah Biological Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 118. Sinovetah Biological Pharmaceutical Major Business
Table 119. Sinovetah Biological Pharmaceutical Highly Pathogenic PRRS Live Vaccine Product and Services
Table 120. Sinovetah Biological Pharmaceutical Highly Pathogenic PRRS Live Vaccine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 121. Sinovetah Biological Pharmaceutical Recent Developments/Updates
Table 122. Sinovetah Biological Pharmaceutical Competitive Strengths & Weaknesses
Table 123. TECON Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 124. TECON Pharmaceutical Major Business
Table 125. TECON Pharmaceutical Highly Pathogenic PRRS Live Vaccine Product and Services
Table 126. TECON Pharmaceutical Highly Pathogenic PRRS Live Vaccine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 127. TECON Pharmaceutical Recent Developments/Updates
Table 128. TECON Pharmaceutical Competitive Strengths & Weaknesses
Table 129. Harbin Veken Biotechnology Basic Information, Manufacturing Base and Competitors
Table 130. Harbin Veken Biotechnology Major Business
Table 131. Harbin Veken Biotechnology Highly Pathogenic PRRS Live Vaccine Product and Services
Table 132. Harbin Veken Biotechnology Highly Pathogenic PRRS Live Vaccine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 133. Harbin Veken Biotechnology Recent Developments/Updates
Table 134. Harbin Veken Biotechnology Competitive Strengths & Weaknesses
Table 135. CAHIC Basic Information, Manufacturing Base and Competitors
Table 136. CAHIC Major Business
Table 137. CAHIC Highly Pathogenic PRRS Live Vaccine Product and Services
Table 138. CAHIC Highly Pathogenic PRRS Live Vaccine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 139. CAHIC Recent Developments/Updates
Table 140. CAHIC Competitive Strengths & Weaknesses
Table 141. Huapai Biotechnology Group Basic Information, Manufacturing Base and Competitors
Table 142. Huapai Biotechnology Group Major Business
Table 143. Huapai Biotechnology Group Highly Pathogenic PRRS Live Vaccine Product and Services
Table 144. Huapai Biotechnology Group Highly Pathogenic PRRS Live Vaccine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 145. Huapai Biotechnology Group Recent Developments/Updates
Table 146. Huapai Biotechnology Group Competitive Strengths & Weaknesses
Table 147. Chengdu Shiji Biological Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 148. Chengdu Shiji Biological Pharmaceutical Major Business
Table 149. Chengdu Shiji Biological Pharmaceutical Highly Pathogenic PRRS Live Vaccine Product and Services
Table 150. Chengdu Shiji Biological Pharmaceutical Highly Pathogenic PRRS Live Vaccine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 151. Chengdu Shiji Biological Pharmaceutical Recent Developments/Updates
Table 152. Chengdu Shiji Biological Pharmaceutical Competitive Strengths & Weaknesses
Table 153. Jilin Heyuan Biotechnology Basic Information, Manufacturing Base and Competitors
Table 154. Jilin Heyuan Biotechnology Major Business
Table 155. Jilin Heyuan Biotechnology Highly Pathogenic PRRS Live Vaccine Product and Services
Table 156. Jilin Heyuan Biotechnology Highly Pathogenic PRRS Live Vaccine Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 157. Jilin Heyuan Biotechnology Recent Developments/Updates
Table 158. Jilin Heyuan Biotechnology Competitive Strengths & Weaknesses
Table 159. Global Key Players of Highly Pathogenic PRRS Live Vaccine Upstream (Raw Materials)
Table 160. Global Highly Pathogenic PRRS Live Vaccine Typical Customers
Table 161. Highly Pathogenic PRRS Live Vaccine Typical Distributors
LIST OF FIGURES
Figure 1. Highly Pathogenic PRRS Live Vaccine Picture
Figure 2. World Highly Pathogenic PRRS Live Vaccine Production Value: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Highly Pathogenic PRRS Live Vaccine Production Value and Forecast (2021-2032) & (USD Million)
Figure 4. World Highly Pathogenic PRRS Live Vaccine Production (2021-2032) & (K Dose)
Figure 5. World Highly Pathogenic PRRS Live Vaccine Average Price (2021-2032) & (US$/Dose)
Figure 6. World Highly Pathogenic PRRS Live Vaccine Production Value Market Share by Region (2021-2032)
Figure 7. World Highly Pathogenic PRRS Live Vaccine Production Market Share by Region (2021-2032)
Figure 8. North America Highly Pathogenic PRRS Live Vaccine Production (2021-2032) & (K Dose)
Figure 9. China Highly Pathogenic PRRS Live Vaccine Production (2021-2032) & (K Dose)
Figure 10. Highly Pathogenic PRRS Live Vaccine Market Drivers
Figure 11. Factors Affecting Demand
Figure 12. World Highly Pathogenic PRRS Live Vaccine Consumption (2021-2032) & (K Dose)
Figure 13. World Highly Pathogenic PRRS Live Vaccine Consumption Market Share by Region (2021-2032)
Figure 14. United States Highly Pathogenic PRRS Live Vaccine Consumption (2021-2032) & (K Dose)
Figure 15. China Highly Pathogenic PRRS Live Vaccine Consumption (2021-2032) & (K Dose)
Figure 16. Europe Highly Pathogenic PRRS Live Vaccine Consumption (2021-2032) & (K Dose)
Figure 17. Japan Highly Pathogenic PRRS Live Vaccine Consumption (2021-2032) & (K Dose)
Figure 18. South Korea Highly Pathogenic PRRS Live Vaccine Consumption (2021-2032) & (K Dose)
Figure 19. ASEAN Highly Pathogenic PRRS Live Vaccine Consumption (2021-2032) & (K Dose)
Figure 20. India Highly Pathogenic PRRS Live Vaccine Consumption (2021-2032) & (K Dose)
Figure 21. Producer Shipments of Highly Pathogenic PRRS Live Vaccine by Manufacturer Revenue ($MM) and Market Share (%): 2025
Figure 22. Global Four-firm Concentration Ratios (CR4) for Highly Pathogenic PRRS Live Vaccine Markets in 2025
Figure 23. Global Four-firm Concentration Ratios (CR8) for Highly Pathogenic PRRS Live Vaccine Markets in 2025
Figure 24. United States VS China: Highly Pathogenic PRRS Live Vaccine Production Value Market Share Comparison (2021 & 2025 & 2032)
Figure 25. United States VS China: Highly Pathogenic PRRS Live Vaccine Production Market Share Comparison (2021 & 2025 & 2032)
Figure 26. United States VS China: Highly Pathogenic PRRS Live Vaccine Consumption Market Share Comparison (2021 & 2025 & 2032)
Figure 27. United States Based Manufacturers Highly Pathogenic PRRS Live Vaccine Production Market Share 2025
Figure 28. China Based Manufacturers Highly Pathogenic PRRS Live Vaccine Production Market Share 2025
Figure 29. Rest of World Based Manufacturers Highly Pathogenic PRRS Live Vaccine Production Market Share 2025
Figure 30. World Highly Pathogenic PRRS Live Vaccine Production Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 31. World Highly Pathogenic PRRS Live Vaccine Production Value Market Share by Type in 2025
Figure 32. JXA1-R Strain Live Vaccine
Figure 33. TJM-F92 Strain Live Vaccine
Figure 34. GDr180 Strain Live Vaccine
Figure 35. Others
Figure 36. World Highly Pathogenic PRRS Live Vaccine Production Market Share by Type (2021-2032)
Figure 37. World Highly Pathogenic PRRS Live Vaccine Production Value Market Share by Type (2021-2032)
Figure 38. World Highly Pathogenic PRRS Live Vaccine Average Price by Type (2021-2032) & (US$/Dose)
Figure 39. World Highly Pathogenic PRRS Live Vaccine Production Value by Product Combination, (USD Million), 2021 & 2025 & 2032
Figure 40. World Highly Pathogenic PRRS Live Vaccine Production Value Market Share by Product Combination in 2025
Figure 41. Monovalent Live Vaccine
Figure 42. Combination Live Vaccine
Figure 43. World Highly Pathogenic PRRS Live Vaccine Production Market Share by Product Combination (2021-2032)
Figure 44. World Highly Pathogenic PRRS Live Vaccine Production Value Market Share by Product Combination (2021-2032)
Figure 45. World Highly Pathogenic PRRS Live Vaccine Average Price by Product Combination (2021-2032) & (US$/Dose)
Figure 46. World Highly Pathogenic PRRS Live Vaccine Production Value by Dose Pack Size, (USD Million), 2021 & 2025 & 2032
Figure 47. World Highly Pathogenic PRRS Live Vaccine Production Value Market Share by Dose Pack Size in 2025
Figure 48. Small Pack (Below 20 Doses per Vial)
Figure 49. Medium Pack (20–50 Doses per Vial)
Figure 50. Large Pack (Above 50 Doses per Vial)
Figure 51. World Highly Pathogenic PRRS Live Vaccine Production Market Share by Dose Pack Size (2021-2032)
Figure 52. World Highly Pathogenic PRRS Live Vaccine Production Value Market Share by Dose Pack Size (2021-2032)
Figure 53. World Highly Pathogenic PRRS Live Vaccine Average Price by Dose Pack Size (2021-2032) & (US$/Dose)
Figure 54. World Highly Pathogenic PRRS Live Vaccine Production Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 55. World Highly Pathogenic PRRS Live Vaccine Production Value Market Share by Application in 2025
Figure 56. Large-scale Integrated Pig Farming Groups
Figure 57. Breeding and Multiplier Farms
Figure 58. Animal Disease Control Institutions
Figure 59. Others
Figure 60. World Highly Pathogenic PRRS Live Vaccine Production Market Share by Application (2021-2032)
Figure 61. World Highly Pathogenic PRRS Live Vaccine Production Value Market Share by Application (2021-2032)
Figure 62. World Highly Pathogenic PRRS Live Vaccine Average Price by Application (2021-2032) & (US$/Dose)
Figure 63. Highly Pathogenic PRRS Live Vaccine Industry Chain
Figure 64. Highly Pathogenic PRRS Live Vaccine Procurement Model
Figure 65. Highly Pathogenic PRRS Live Vaccine Sales Model
Figure 66. Highly Pathogenic PRRS Live Vaccine Sales Channels, Direct Sales, and Distribution
Figure 67. Methodology
Figure 68. Research Process and Data Source
Figure 1. Highly Pathogenic PRRS Live Vaccine Picture
Figure 2. World Highly Pathogenic PRRS Live Vaccine Production Value: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Highly Pathogenic PRRS Live Vaccine Production Value and Forecast (2021-2032) & (USD Million)
Figure 4. World Highly Pathogenic PRRS Live Vaccine Production (2021-2032) & (K Dose)
Figure 5. World Highly Pathogenic PRRS Live Vaccine Average Price (2021-2032) & (US$/Dose)
Figure 6. World Highly Pathogenic PRRS Live Vaccine Production Value Market Share by Region (2021-2032)
Figure 7. World Highly Pathogenic PRRS Live Vaccine Production Market Share by Region (2021-2032)
Figure 8. North America Highly Pathogenic PRRS Live Vaccine Production (2021-2032) & (K Dose)
Figure 9. China Highly Pathogenic PRRS Live Vaccine Production (2021-2032) & (K Dose)
Figure 10. Highly Pathogenic PRRS Live Vaccine Market Drivers
Figure 11. Factors Affecting Demand
Figure 12. World Highly Pathogenic PRRS Live Vaccine Consumption (2021-2032) & (K Dose)
Figure 13. World Highly Pathogenic PRRS Live Vaccine Consumption Market Share by Region (2021-2032)
Figure 14. United States Highly Pathogenic PRRS Live Vaccine Consumption (2021-2032) & (K Dose)
Figure 15. China Highly Pathogenic PRRS Live Vaccine Consumption (2021-2032) & (K Dose)
Figure 16. Europe Highly Pathogenic PRRS Live Vaccine Consumption (2021-2032) & (K Dose)
Figure 17. Japan Highly Pathogenic PRRS Live Vaccine Consumption (2021-2032) & (K Dose)
Figure 18. South Korea Highly Pathogenic PRRS Live Vaccine Consumption (2021-2032) & (K Dose)
Figure 19. ASEAN Highly Pathogenic PRRS Live Vaccine Consumption (2021-2032) & (K Dose)
Figure 20. India Highly Pathogenic PRRS Live Vaccine Consumption (2021-2032) & (K Dose)
Figure 21. Producer Shipments of Highly Pathogenic PRRS Live Vaccine by Manufacturer Revenue ($MM) and Market Share (%): 2025
Figure 22. Global Four-firm Concentration Ratios (CR4) for Highly Pathogenic PRRS Live Vaccine Markets in 2025
Figure 23. Global Four-firm Concentration Ratios (CR8) for Highly Pathogenic PRRS Live Vaccine Markets in 2025
Figure 24. United States VS China: Highly Pathogenic PRRS Live Vaccine Production Value Market Share Comparison (2021 & 2025 & 2032)
Figure 25. United States VS China: Highly Pathogenic PRRS Live Vaccine Production Market Share Comparison (2021 & 2025 & 2032)
Figure 26. United States VS China: Highly Pathogenic PRRS Live Vaccine Consumption Market Share Comparison (2021 & 2025 & 2032)
Figure 27. United States Based Manufacturers Highly Pathogenic PRRS Live Vaccine Production Market Share 2025
Figure 28. China Based Manufacturers Highly Pathogenic PRRS Live Vaccine Production Market Share 2025
Figure 29. Rest of World Based Manufacturers Highly Pathogenic PRRS Live Vaccine Production Market Share 2025
Figure 30. World Highly Pathogenic PRRS Live Vaccine Production Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 31. World Highly Pathogenic PRRS Live Vaccine Production Value Market Share by Type in 2025
Figure 32. JXA1-R Strain Live Vaccine
Figure 33. TJM-F92 Strain Live Vaccine
Figure 34. GDr180 Strain Live Vaccine
Figure 35. Others
Figure 36. World Highly Pathogenic PRRS Live Vaccine Production Market Share by Type (2021-2032)
Figure 37. World Highly Pathogenic PRRS Live Vaccine Production Value Market Share by Type (2021-2032)
Figure 38. World Highly Pathogenic PRRS Live Vaccine Average Price by Type (2021-2032) & (US$/Dose)
Figure 39. World Highly Pathogenic PRRS Live Vaccine Production Value by Product Combination, (USD Million), 2021 & 2025 & 2032
Figure 40. World Highly Pathogenic PRRS Live Vaccine Production Value Market Share by Product Combination in 2025
Figure 41. Monovalent Live Vaccine
Figure 42. Combination Live Vaccine
Figure 43. World Highly Pathogenic PRRS Live Vaccine Production Market Share by Product Combination (2021-2032)
Figure 44. World Highly Pathogenic PRRS Live Vaccine Production Value Market Share by Product Combination (2021-2032)
Figure 45. World Highly Pathogenic PRRS Live Vaccine Average Price by Product Combination (2021-2032) & (US$/Dose)
Figure 46. World Highly Pathogenic PRRS Live Vaccine Production Value by Dose Pack Size, (USD Million), 2021 & 2025 & 2032
Figure 47. World Highly Pathogenic PRRS Live Vaccine Production Value Market Share by Dose Pack Size in 2025
Figure 48. Small Pack (Below 20 Doses per Vial)
Figure 49. Medium Pack (20–50 Doses per Vial)
Figure 50. Large Pack (Above 50 Doses per Vial)
Figure 51. World Highly Pathogenic PRRS Live Vaccine Production Market Share by Dose Pack Size (2021-2032)
Figure 52. World Highly Pathogenic PRRS Live Vaccine Production Value Market Share by Dose Pack Size (2021-2032)
Figure 53. World Highly Pathogenic PRRS Live Vaccine Average Price by Dose Pack Size (2021-2032) & (US$/Dose)
Figure 54. World Highly Pathogenic PRRS Live Vaccine Production Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 55. World Highly Pathogenic PRRS Live Vaccine Production Value Market Share by Application in 2025
Figure 56. Large-scale Integrated Pig Farming Groups
Figure 57. Breeding and Multiplier Farms
Figure 58. Animal Disease Control Institutions
Figure 59. Others
Figure 60. World Highly Pathogenic PRRS Live Vaccine Production Market Share by Application (2021-2032)
Figure 61. World Highly Pathogenic PRRS Live Vaccine Production Value Market Share by Application (2021-2032)
Figure 62. World Highly Pathogenic PRRS Live Vaccine Average Price by Application (2021-2032) & (US$/Dose)
Figure 63. Highly Pathogenic PRRS Live Vaccine Industry Chain
Figure 64. Highly Pathogenic PRRS Live Vaccine Procurement Model
Figure 65. Highly Pathogenic PRRS Live Vaccine Sales Model
Figure 66. Highly Pathogenic PRRS Live Vaccine Sales Channels, Direct Sales, and Distribution
Figure 67. Methodology
Figure 68. Research Process and Data Source
